Skip to content
Contact Us Today|info@empharmd.com
EM PharmD Logo

Drugs, Knowledge & Health

  • Home
  • About The Bloggers
  • EM PharmD Core
  • Wellness in EM PharmD
Previous Next

Paging Goldilocks to the ER: Acute Pain Management in the Emergency Department, Part I

By EM PharmD|2013-08-01T10:00:00-05:00August 1st, 2013|EM PharmD Blog|3 Comments

Share This Story, Choose Your Platform!

FacebookTwitterLinkedInRedditWhatsappTumblrPinterestVkEmail

About the Author: EM PharmD

Related Posts

  • Single Dose Aminoglycoside For Urinary Tract Infections

    Single Dose Aminoglycoside For Urinary Tract Infections

  • I Have Andexanet Issues, 2: A Formulary Toolkit

    I Have Andexanet Issues, 2: A Formulary Toolkit

  • Apixaban or Rivaroxaban: The Jury’s Still out

    Apixaban or Rivaroxaban: The Jury’s Still out

  • The 5 Types of Interviewees: Reflections of a PGY-1 Resident

    The 5 Types of Interviewees: Reflections of a PGY-1 Resident

  • How to Wean a Guy (after at least) 10 Days

    How to Wean a Guy (after at least) 10 Days

3 Comments

  1. Seth Trueger August 1, 2013 at 10:14 am - Reply

    Good summary! I agree that 4mg of morphine is generally not enough, but, as you note, there's a lot of resistance to “appropriate” doses. I tend to give 4mg — which everyone is comfortable giving — and just repeating as often as necessary.

  2. Stephen Rolfe August 23, 2013 at 8:07 pm - Reply

    Great post. I think one of the best ways to optimize pain management in the ED is to implement a nursing-driven pain management protocol. We recently developed and implemented a protocol at Maine Medical Center, where physicians can pick from either normal weight-based opioid dosing in patients at low-risk of AEs or a decreased weight-based regimen in patients at high-risk of AEs. Patients must present with moderate to severe acute pain with a VAS of 4-10 and our goal is to reduce pain by at least 50% within the first hour. One of the most crucial aspects of the protocol is proper re-evaluation of the patient, so I think the patient should ideally be reevaluated at least every 20 minutes until pain has been controlled. In addition to opioids and adjunctive medications (non-opioids, diphenhydramine, ketorolac, etc.), non-pharmacological interventions are also implemented. Exclusion criteria from the protocol includes: critical illness, intoxication/AMS, chronic pain, or opioid allergy. Obviously there are numerous barriers to protocols like this (i.e. need for department-wide buy-in), but I think it is worth a shot. So far, the protocol has been successful, but this is in a small subset of patients. It will be interesting to see how it plays out for us over the next year…

  3. j0najum August 24, 2013 at 4:40 am - Reply

    great post!

Leave A Comment Cancel reply

Recent Posts

  • Free Book Giveaway
  • L-carnitine and the Nike Oregon Project
  • Diphacinone Toxicity
  • Is Thiamine IV Push Safe?
  • Cannabinoid Hyperemesis Syndrome (CHS): Getting “Into the Weeds” on a Complication of Chronic Marijuana Use

Categories

  • Classic EM PharmD
  • EM PharmD Blog
  • EM PharmD Core
  • Wellness in EM PharmD

Recent Comments

  • Deborah Silver Goodman on The Tramadol of Antimicrobials: Fluoroquinolones
  • Anticoagulation Reversal Survey Help – EM PharmD on FTFY: Prothrombin Complex Concentrate, That Is
  • Acute Decompensated Heart Failure – EM PharmD on Pharmacy Consult: Nitroglycerin Paste to IV Conversion
  • Robert Pugliese on Emergent Treatment of Arrhythmias Associated With Wolff-Parkinson-White Syndrome
  • Meghan Groth on Emergent Treatment of Arrhythmias Associated With Wolff-Parkinson-White Syndrome

Archives

  • October 2019
  • September 2019
  • July 2019
  • June 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • August 2017
  • May 2017
  • April 2017
  • March 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012

DISCLAIMER

This blog is intended to reflect my personal opinions and beliefs and not those of any other individual, department, institution, University or any other organization. Any opinion given is just that, an opinion, and is not intended to be used as clinical advice for patient care. I reserve the right to edit or remove any post or comment found not to be relevant.

RECENT POSTS

  • Free Book Giveaway
  • L-carnitine and the Nike Oregon Project
  • Diphacinone Toxicity
  • Is Thiamine IV Push Safe?
  • Cannabinoid Hyperemesis Syndrome (CHS): Getting “Into the Weeds” on a Complication of Chronic Marijuana Use
Copyright 2019 - EM PharmD | All Rights Reserved